IRIS
ZAZZI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.067
EU - Europa 20.348
AS - Asia 11.088
SA - Sud America 2.119
AF - Africa 801
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 13
Totale 60.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.680
GB - Regno Unito 4.325
RU - Federazione Russa 3.931
CN - Cina 3.419
SG - Singapore 3.291
IT - Italia 3.288
IE - Irlanda 2.544
BR - Brasile 1.735
VN - Vietnam 1.317
SE - Svezia 1.298
DE - Germania 1.238
UA - Ucraina 1.193
FR - Francia 1.142
HK - Hong Kong 1.043
FI - Finlandia 583
KR - Corea 519
ZA - Sudafrica 459
IN - India 391
BD - Bangladesh 226
CA - Canada 185
ES - Italia 179
AR - Argentina 139
NG - Nigeria 124
IQ - Iraq 120
NL - Olanda 120
MX - Messico 113
TR - Turchia 105
JP - Giappone 94
BE - Belgio 91
AT - Austria 82
PK - Pakistan 79
PL - Polonia 77
ID - Indonesia 72
EC - Ecuador 59
UZ - Uzbekistan 52
KE - Kenya 45
SA - Arabia Saudita 40
VE - Venezuela 40
CL - Cile 39
CO - Colombia 37
CZ - Repubblica Ceca 36
AE - Emirati Arabi Uniti 34
LT - Lituania 31
MA - Marocco 31
MY - Malesia 30
PH - Filippine 29
AU - Australia 27
PY - Paraguay 26
JO - Giordania 25
EG - Egitto 22
IR - Iran 22
NP - Nepal 19
CI - Costa d'Avorio 18
KZ - Kazakistan 18
EE - Estonia 17
ET - Etiopia 17
TH - Thailandia 17
GR - Grecia 16
LU - Lussemburgo 16
PT - Portogallo 16
DZ - Algeria 15
JM - Giamaica 15
LB - Libano 15
PA - Panama 15
UY - Uruguay 15
DO - Repubblica Dominicana 14
IL - Israele 14
PE - Perù 14
SK - Slovacchia (Repubblica Slovacca) 13
AL - Albania 12
BO - Bolivia 12
CH - Svizzera 12
KG - Kirghizistan 12
TN - Tunisia 12
AZ - Azerbaigian 11
DK - Danimarca 11
LV - Lettonia 11
RO - Romania 11
RS - Serbia 11
UG - Uganda 11
HN - Honduras 10
CR - Costa Rica 9
EU - Europa 9
BG - Bulgaria 8
BH - Bahrain 8
SN - Senegal 8
BY - Bielorussia 7
GE - Georgia 7
HU - Ungheria 7
LK - Sri Lanka 7
OM - Oman 7
PS - Palestinian Territory 7
TW - Taiwan 7
GT - Guatemala 6
SY - Repubblica araba siriana 6
AO - Angola 5
GA - Gabon 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
Totale 60.373
Salva come PNG Salva come JPEG
Città #
Southend 3.724
Dallas 3.036
Fairfield 2.521
Dublin 2.512
Ashburn 1.850
Singapore 1.811
Houston 1.666
Chandler 1.518
Woodbridge 1.130
Santa Clara 1.095
Moscow 1.045
Hong Kong 1.004
Jacksonville 966
Seattle 939
Wilmington 932
San Jose 889
Milan 863
Cambridge 851
Ann Arbor 843
Beijing 834
Siena 610
Hefei 602
Council Bluffs 537
Seoul 511
Munich 467
Princeton 433
The Dalles 417
Johannesburg 406
Ho Chi Minh City 389
Los Angeles 380
Rome 337
New York 326
Lauterbourg 304
Nanjing 295
Helsinki 285
Hanoi 275
Menlo Park 222
Dong Ket 187
Boardman 183
San Mateo 181
São Paulo 161
Buffalo 148
San Diego 139
Shanghai 120
Abuja 119
Columbus 115
Bengaluru 114
Nanchang 113
London 109
Málaga 109
Redondo Beach 104
Dearborn 93
Frankfurt am Main 87
Orem 86
Tokyo 80
Brussels 79
Florence 76
Nuremberg 74
Düsseldorf 72
Chennai 70
Figino 67
Tianjin 67
Chicago 64
Turku 61
Da Nang 60
Shenyang 60
Warsaw 59
Montreal 57
Turin 56
Toronto 55
San Francisco 54
Atlanta 51
Hebei 51
Phoenix 51
Vienna 51
Changsha 50
Rio de Janeiro 50
Bologna 49
Hangzhou 49
Denver 47
Lappeenranta 47
Amsterdam 45
Brooklyn 45
Haiphong 45
Manchester 44
Naples 44
Tashkent 43
Baghdad 42
Belo Horizonte 42
Jiaxing 42
Lancaster 41
Portsmouth 40
Dhaka 39
Mexico City 39
Zhengzhou 38
Jinan 37
Norwalk 37
Guangzhou 36
Kunming 36
Stockholm 34
Totale 41.369
Salva come PNG Salva come JPEG
Nome #
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-infected subjects 629
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 629
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 569
Surrogate markers as a guide to evaluate response to antiretroviral therapy 490
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 331
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 319
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 316
A child with vestibular neuritis. Is adenovirus implicated? 315
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 315
A novel methodology for large-scale phylogeny partition 307
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 306
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 303
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 302
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 300
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 299
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 298
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 297
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 297
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 297
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 289
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 286
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 286
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 282
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 281
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 280
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 277
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples 274
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 269
Anticipating policy considerations for a future HIV vaccine: a preliminary study 267
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 264
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 262
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 262
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 261
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 261
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 261
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 260
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 259
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 257
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 257
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 256
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. 255
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 255
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 254
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. 253
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 253
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 252
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 251
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 250
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 248
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 248
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 248
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 248
HIV-1 and human myelin proteins share an antigenic determinant 245
An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype 244
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 242
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 241
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 239
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 239
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. 239
Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients 238
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 238
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 237
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 237
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 237
Advantages of Predicted Phenotypes and Statistical Learning Models in Inferring Virological Response to Antiretroviral Therapy from HIV Genotype 236
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 235
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 235
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 235
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 234
Focal myositis: a polymerase chain reaction analysis for a viral etiology 232
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 232
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 231
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 229
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 228
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 228
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database 227
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 227
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. 226
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 225
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. 225
An update to the HIV-TRePS system: The development of new computational models that do not require a genotype to predict HIV treatment outcomes 224
The global spread of HIV-1 subtype B epidemic 222
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 221
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy 219
Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? 219
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 218
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 217
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 216
Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case 215
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 215
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 214
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 212
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 212
European guidelines on the clinical management of HIV-1 tropism testing 211
Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy 206
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 206
Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 plasma RNA. 205
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 205
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 205
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 204
Totale 26.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.150
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.890 212 469 268 397 198 147 209 173 301 396 360 760
2022/20235.234 312 514 617 725 505 1.030 148 432 491 158 201 101
2023/20243.724 157 98 315 210 78 1.083 1.277 103 18 63 82 240
2024/20258.759 189 400 838 425 1.002 552 376 562 811 436 910 2.258
2025/202620.929 1.649 2.757 2.628 2.291 3.804 761 2.242 829 714 1.075 572 1.607
2026/2027461 461 0 0 0 0 0 0 0 0 0 0 0
Totale 61.257